Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants

您当前的位置：

首页 >

文章列表页 >

Short communication | 更新时间：2023-08-29

- Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
- Genes & Diseases Vol. 10, Issue 3, (2023)
- 作者机构：
  
  1. KMD Bioscience (Tianjin) Company Limited,Tianjin,China,301723
  2. Henan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical University,Henan,Xinxiang,China,453003
  3. Department of Pathophysiology, School of Basic Medical Sciences, Academy of Medical Science, College of Medicine, Zhengzhou University,Henan,Zhengzhou,China,450001
  4. US (Henan) Hormel Cancer Institute,,, China,Henan,Zhengzhou,China,450008
  5. Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University,Henan,Xinxiang,China,453003
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.05.027
  CLC：
- Published：2023，
  
  Published Online：1 May 2023，
扫描看全文
Qianqian Zheng, Liangwei Duan, Zhihua Jiang, et al. Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants. [J]. Genes & Diseases 10(3).(2023)
DOI：

Qianqian Zheng, Liangwei Duan, Zhihua Jiang, et al. Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants. [J]. Genes & Diseases 10(3).(2023) DOI： 10.1016/j.gendis.2022.05.027.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰